Valuation: Shield Therapeutics plc

Market Cap 33.7M 44.9M 40.27M 37.11M 63.78M 4.21B 65.56M 444M 177M 2.26B 169M 165M 7.13B P/E 2026 *
-
P/E 2027 * 2.11x
Enterprise Value 54.99M 73.27M 65.71M 60.55M 104M 6.87B 107M 725M 289M 3.68B 275M 269M 11.63B EV / Sales 2026 *
1.23x
EV / Sales 2027 * 1.1x
Free-Float
38.5%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Shield Therapeutics plc

1 day+4.76%
1 week+8.20%
Current month-41.59%
1 month-37.14%
3 months-14.29%
6 months-52.86%
Current year-66.50%
1 week 3
Extreme 3
3.6
1 month 2.93
Extreme 2.926
5.8
Current year 2.93
Extreme 2.926
12.5
1 year 2.93
Extreme 2.926
12.5
3 years 1.06
Extreme 1.0625
12.5
5 years 1.06
Extreme 1.0625
52
10 years 1.06
Extreme 1.0625
202
Manager TitleAgeSince
Chief Executive Officer 64 24/07/2024
Director of Finance/CFO 50 01/09/2026
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 68 01/02/2016
Chairman 70 18/06/2020
Director/Board Member 59 26/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
10/14/25 A Free

Chief Executive Officer

1,547,262 0.1485%
2/13/25 A Free

Chief Executive Officer

5,000,000 0.4800%
2/13/25 A Buy

Chief Executive Officer

575,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
+4.76%+8.20%-50.38%-44.44% 45.21M
+0.84%+0.91%+47.13%+137.94% 1,258B
-0.36%+5.66%+49.26%+90.99% 679B
+0.14%+2.60%+34.17%+111.73% 518B
+0.17%+2.76%+44.07%+69.71% 390B
-1.22%+1.21%+68.78%+44.41% 367B
+0.76%+2.27%+31.59%+60.36% 307B
-1.29%+0.90%+5.77%+37.60% 293B
-0.27%+0.42%+43.11%+73.28% 252B
+0.35%+1.31%+43.61%+123.49% 210B
Average +0.44%-3.33%+31.71%+70.51% 427B
Weighted average by Cap. +0.12%+1.17%+43.11%+96.08%

Financials

2026 *2027 *
Net sales 44.57M 59.38M 53.25M 49.08M 84.35M 5.57B 86.71M 588M 234M 2.98B 223M 218M 9.43B 53.22M 70.9M 63.58M 58.6M 101M 6.65B 104M 702M 280M 3.56B 266M 260M 11.26B
Net income -2.91M -3.87M -3.47M -3.2M -5.5M -363M -5.65M -38.32M -15.27M -195M -14.53M -14.22M -615M 6.48M 8.64M 7.75M 7.14M 12.27M 810M 12.61M 85.49M 34.06M 434M 32.42M 31.73M 1.37B
Net Debt 21.29M 28.37M 25.44M 23.44M 40.29M 2.66B 41.42M 281M 112M 1.42B 106M 104M 4.5B 25.07M 33.4M 29.95M 27.6M 47.44M 3.13B 48.77M 330M 132M 1.68B 125M 123M 5.3B
Projected Income Statement - Annual - Shield Therapeutics plc
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Shield Therapeutics plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0315GBP
Average target price
0.1567GBP
Spread / Average Target
+397.37%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Shield Therapeutics plc